Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients With Diabetes Mellitus
TEMD
1 other identifier
observational
5,240
1 country
1
Brief Summary
This study evaluates the overall cardiovascular risk status and best predictors of optimal metabolic control of Turkish adult patients with diabetes mellitus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2017
CompletedFirst Submitted
Initial submission to the registry
September 24, 2017
CompletedFirst Posted
Study publicly available on registry
March 6, 2018
CompletedMarch 6, 2018
February 1, 2018
3 months
September 24, 2017
February 27, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Glycemia control status of Turkish adult patients with diabetes mellitus
Glycemia control will be defined as good control if the mean HbA1c level of patients \< 7% or poor control if the mean HbA1c level of patient \> 7%
7 days
Secondary Outcomes (3)
Blood pressure control status of Turkish adult patients with diabetes mellitus
7 days
Lipid control status of Turkish adult patients with diabetes mellitus.
7 days.
Weight control status of Turkish adult patients with diabetes mellitus.
7 days.
Study Arms (1)
Patients with diabetes mellitus
Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
Interventions
Eligibility Criteria
Patients with type 1 or type 2 diabetes who were under follow-up in the same tertiary endocrine unit for at least a year were enrolled.
You may qualify if:
- Patients with type 1 or type 2 diabetes
- Upper than 18 years old
- To be under follow-up in the same center for at least one year.
You may not qualify if:
- Pregnancy
- Younger than 18 years old,
- History of decompensated liver disease,
- History of psychiatric disorders interfering cognition or compliance
- History of bariatric surgery
- History of renal replacement therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Gulhane School of Medicine Department of Endocrinology and Metabolism
Ankara, 06018, Turkey (Türkiye)
Related Publications (1)
Sonmez A, Tasci I, Demirci I, Haymana C, Barcin C, Aydin H, Cetinkalp S, Ozturk FY, Gul K, Sabuncu T, Satman I, Bayram F; TEMD Study Group. A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study. Diabetes Ther. 2020 May;11(5):1045-1059. doi: 10.1007/s13300-020-00779-0. Epub 2020 Feb 22.
PMID: 32088879DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr.
Study Record Dates
First Submitted
September 24, 2017
First Posted
March 6, 2018
Study Start
April 1, 2017
Primary Completion
June 30, 2017
Study Completion
June 30, 2017
Last Updated
March 6, 2018
Record last verified: 2018-02
Data Sharing
- IPD Sharing
- Will not share